- Home
- IQ vs DNLI Comparison
IQ vs DNLI Comparison
Compare IQ & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IQ | DNLI |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | IQ | DNLI |
|---|---|---|
| Price | $2.02 | $17.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $2.87 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 10.1M | 1.7M |
| Earning Date | 11-18-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,808,085,043.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.72 | $3,993.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $10.57 |
| 52 Week High | $2.84 | $25.48 |
Technical Indicators
Market Signals| Indicator | IQ | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 46.83 |
| Support Level | $1.97 | $17.65 |
| Resistance Level | $2.08 | $20.61 |
| Average True Range (ATR) | 0.07 | 1.05 |
| MACD | -0.00 | -0.18 |
| Stochastic Oscillator | 20.00 | 16.58 |
Price Performance
Historical ComparisonAbout IQ iQIYI Inc.
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.